Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life (RCT-EPA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02333435
Recruitment Status : Active, not recruiting
First Posted : January 7, 2015
Last Update Posted : November 16, 2018
Sponsor:
Information provided by (Responsible Party):
CHU de Quebec-Universite Laval

Brief Summary:

Prostate cancer, the most frequently diagnosed cancer among occidental men, is associated with a major individual and societal burden. Although still controversial, the literature suggests that a high consumption of omega-3 fatty acids (ω3) has protective effects against prostate cancer. One of the proposed mechanisms of action of ω3 lies in their anti-inflammatory properties. In addition, there are some observational evidences suggesting an association of ω3 intake with a lower rate of depression in cancer patients. However, no clinical study has tested the efficacy of ω3 supplementation on psychological and quality of life outcomes in that population. Several evidences point to a possible involvement of inflammation in psychological issues. Reducing the systemic inflammatory state may have beneficial impact on the quality of life of these patients. Preliminary work from this team of investigators, in a cohort of patients managed with active surveillance for their low-grade prostate cancer, show a strong inverse association between the risk of prostate cancer progression (to high-grade) and the level of prostatic eicosapentanoic acid (EPA- a type of ω3).

HYPOTHESIS: EPA-rich monoglycerides fish oil (MAG-EPA) has global positive effects on prostate cancer cell proliferation, inflammation and on the patient's psychosocial functioning and quality of life.

The investigators propose a double blind, randomized controlled clinical trial. 130 consecutive patients suffering from high-risk prostate cancer who choose to be treated by radical prostatectomy will be eligible to this study. The presence of high-grade cancer will be mandatory.

The intervention, a daily supplementation with 3g supplement of fish oil monoglycerides rich in EPA, vs. placebo capsules containing high oleic sunflower oil, will start six weeks before the prostatectomy and will continue for one year after surgery. The potential confounding variables will be measured before the start of the intervention: age, anthropometric parameters, stage and clinical and pathological tumor grade (Gleason score), pre-operative level of prostate specific antigen and diet.

This project proposes a simple intervention by dietary supplementation that could eventually help to reduce the incidence and/or progression of prostate cancer, and the consequences of its treatment, and thus could contribute to diminish the heavy individual and societal burden of prostate cancer. The clinical data generated by this trial will serve as solid basis for a large-scale phase III clinical trial.


Condition or disease Intervention/treatment Phase
Prostate Cancer Dietary Supplement: EPA Dietary Supplement: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 130 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Étude randomisée, contrôlée, de Phase II, Effets d'un Supplement d'oméga-3 (EPA) Sur l'Inflammation, la prolifération Cellulaire et la qualité de Vie Chez Des Patients Avec Cancer de la Prostate traités Par Prostatectomie Radicale
Actual Study Start Date : January 2015
Estimated Primary Completion Date : February 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Purified EPA group
3g per day of purified EPA, capsules, to be taken once a day, for 14 months.
Dietary Supplement: EPA
3g/day of purified EPA , capsules, taken once daily, for 14 months

Experimental: Placebo group
3 g per day of high-oleic sunflower oil capsules, to be taken once a day, for 14 months.
Dietary Supplement: Placebo
3g/day of placebo (high oleic sunflower oil) , capsules, taken once daily, for 14 months
Other Name: High oleic sunflower oil




Primary Outcome Measures :
  1. Change in Prostate Cancer Proliferative Index [ Time Frame: 6 weeks ]
    At 6 weeks post study entry, the prostate of the patient will be removed by prostatectomy. The tissue will be preserved in paraffin blocks. The tumour will be identified and the level of Ki-67 in the tumour will be quantified.


Secondary Outcome Measures :
  1. Change in Inflammatory mediators levels- Systemic [ Time Frame: 6 weeks, 1 year ]
    The changes in levels of systemic inflammatory mediators, relative to their baseline levels, at the time of radical prostatectomy and at one year post-radical prostatectomy, will be measured. The levels of mediators will be expressed in pg/mL and quantified using validated techniques.

  2. Modulation of Inflammatory mediators levels - Prostatic [ Time Frame: 6 weeks, 1 year ]
    The differences in the levels of expression of inflammatory mediators between both treatment groups will be measured in the peripheral zone of the prostate before surgical prostate dissection/ischemia. The levels of mediators will be expressed in pg/mL and quantified using validated techniques. Further validation could be performed using immunohistochemistry techniques.

  3. Modulation of the Quality of life of patients [ Time Frame: 6 weeks, 3, 6, 9 and 12 months post radical prostatectomy ]
    Validated questionnaires will be used to measure the modulation of the treatment on Quality of Life of the patients, which will include questions on mood, anxiety levels, sleep and cognition.

  4. Modulation of the psychosocial functioning of patients [ Time Frame: 6 weeks, 3, 6, 9 and 12 months post radical prostatectomy ]
    Validated questionnaires will be used to measure the modulation of the treatment on psychosocial functioning of the patients, which will include questions on mood, anxiety levels, sleep and cognition.

  5. Impact of inflammation on Quality of life [ Time Frame: 6 weeks, 3, 6, 9 and 12 months post radical prostatectomy ]
    The impact of changes in inflammatory mediators levels induced by EPA supplementation on quality of life scores will be measured. To do so, we will use appropriate and powerful statistical tests.

  6. Impact of inflammation on psychosocial functioning [ Time Frame: 6 weeks, 3, 6, 9 and 12 months post radical prostatectomy ]
    The impact of changes in inflammatory mediators levels induced by EPA supplementation and changes in psychosocial functioning scores will be measured. To do so, we will use appropriate and powerful statistical tests.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Prostate cancer (Gleason score >= 7)
  • Patient has chosen to undergo radical prostatectomy
  • Patient agrees to stop taking any omega-3 supplements at least 3 months before the start of the study
  • Patient has provided informed consent

Exclusion Criteria:

  • Allergy to fish and sunflower
  • Suffering from a bipolar disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02333435


Locations
Layout table for location information
Canada
Centre de Recherche Clinique et Evaluative en Oncologie - Hotel Dieu de Quebec
Quebec, Canada, G1R 3S1
Sponsors and Collaborators
CHU de Quebec-Universite Laval
Investigators
Layout table for investigator information
Principal Investigator: Vincent Fradet, MD, PhD Laval University and Hotel Dieu-de-Quebec

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: CHU de Quebec-Universite Laval
ClinicalTrials.gov Identifier: NCT02333435     History of Changes
Other Study ID Numbers: A13-10-1012
First Posted: January 7, 2015    Key Record Dates
Last Update Posted: November 16, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by CHU de Quebec-Universite Laval:
Prostatectomy
Omega-3 fatty acids
Quality of life
inflammation
cellular proliferation

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases